strong

Provide free HIV and TB treatment for health workers in need facilitating the delivery of these services in a non-stigmatizing, gender-sensitive, confidential, and convenient setting when there is no staff clinic and/or their own facility does not offer ART, or where health workers prefer services off-site.

Provide universal availability of free and timely PEP to all health care providers, for both
occupational and non-occupational exposures, with appropriate training of counsellors and
information on the benefits and risks provided to all staff.

Introduce new, or refine existing, national policies that ensure priority access for health workers and their families to services for the prevention, treatment and care for HIV and TB.

Children with suspected or confirmed osteoarticular tuberculosis should be treated
with a four-drug regimen (HRZE) for 2 months followed by a two-drug regimen (HR)
for 10 months; the total duration of treatment being 12 months. The doses
recommended for the treatment of osteoarticular tuberculosis are the same as those
described for pulmonary tuberculosis.

Children with suspected or confirmed tuberculous meningitis should be treated with a
four-drug regimen (HRZE) for 2 months, followed by a two-drug regimen (HR) for
10 months; the total duration of treatment being 12 months. The dosages
recommended for the treatment of tuberculous meningitis are the same as those
described for pulmonary tuberculosis.

Streptomycin should not be used as part of first-line treatment regimens for children
with pulmonary tuberculosis or tuberculous peripheral lymphadenitis.

Infants (aged 0–3 months) with suspected or confirmed pulmonary tuberculosis or
tuberculous peripheral lymphadenitis should be promptly treated with the standard
treatment regimens, as described above.

Children with suspected or confirmed pulmonary tuberculosis or tuberculous
peripheral lymphadenitis living in settings with high HIV prevalence (or with
confirmed HIV infection) should not be treated with intermittent regimens (that is,
twice-weekly or thrice-weekly doses).

Children with suspected or confirmed pulmonary tuberculosis or tuberculous
peripheral lymphadenitis who live in settings with low HIV prevalence or low
resistance to isoniazid and children who are HIV-negative can be treated with a threedrug regimen (HRZ) for 2 months followed by a two-drug (HR) regimen for 4 months at the following dosages:
isoniazid (H) – 10 mg/kg (range 10–15 mg/kg); maximum dose 300 mg/day
rifampicin (R) – 15 mg/kg (range 10–20 mg/kg); maximum dose 600 mg/day
pyrazinamide (Z) – 35 mg/kg (30–40 mg/kg).

Children living in settings where the prevalence of the HIV is high or where
resistance to isoniazid is high, or both, with suspected or confirmed pulmonary
tuberculosis or peripheral lymphadenitis; or children with extensive pulmonary
disease living in settings of low HIV prevalence or low isoniazid resistance, should be
treated with a four-drug regimen (HRZE) for 2 months followed by a two-drug
regimen (HR) for 4 months at the following dosages:
isoniazid (H) – 10 mg/kg (range 10–15 mg/kg); maximum dose 300 mg/day